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Abstract
Background: Deficiency in thymidine kinase 2 (TK2) or p53 inducible ribonucleotide reductase small subunit
(p53R2) is associated with tissue specific mitochondrial DNA (mtDNA) depletion. To understand the mechanisms of
the tissue specific mtDNA depletion we systematically studied key enzymes in dTMP synthesis in mitochondrial and
cytosolic extracts prepared from adult rat tissues.
Results: In addition to mitochondrial TK2 a cytosolic isoform of TK2 was characterized, which showed similar
substrate specificity to the mitochondrial TK2. Total TK activity was highest in spleen and lowest in skeletal muscle.
Thymidylate synthase (TS) was detected in cytosols and its activity was high in spleen but low in other tissues. TS
protein levels were high in heart, brain and skeletal muscle, which deviated from TS activity levels. The p53R2
proteins were at similar levels in all tissues except liver where it was ~ 6-fold lower. Our results strongly indicate
that mitochondria in most tissues are capable of producing enough dTTP for mtDNA replication via mitochondrial
TK2, but skeletal muscle mitochondria do not and are most likely dependent on both the salvage and de novo
synthesis pathways.
Conclusion: These results provide important information concerning mechanisms for the tissue dependent
variation of dTTP synthesis and explained why deficiency in TK2 or p53R2 leads to skeletal muscle dysfunctions.
Furthermore, the presence of a putative cytosolic TK2-like enzyme may provide basic knowledge for the
understanding of deoxynucleoside-based therapy for mitochondrial disorders.
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Background
Thymidylate (dTMP) is an essential building block of
DNA and synthesized by the salvage and the de novo
pathways (Fig. 1). In the salvage pathway dTMP is pro-
duced by thymidine (dT) phosphorylation catalysed by
thymidine kinases (TK1 and TK2) and in the de novo
pathway by deoxyuridylate (dUMP) methylation cata-
lysed by thymidylate synthase (TS). TK1 is a cytosolic
enzyme expressed mainly in proliferating tissues [1, 2].
Mitochondrial TK2, on the other hand, is constitutively
expressed [3, 4]. Determination of TK1 and TK2 activity
in tissue or cell extracts is complicated due to the fact
that both enzymes have overlapping substrate specificity
[5–7]. Cytosolic deoxycytidine kinase (dCK), mainly
expressed in lymphoid tissues, catalyzes the phosphoryl-
ation of deoxycytidine (dC) to dCMP, which can be fur-
ther phosphorylated to dCTP or deaminated to dUMP
and used for dTMP synthesis (Fig. 1) [8, 9]. In post mi-
totic tissues ribonucleotide reductase (RNR) activity is
minimal since the expression of the small subunit is S-
phase specific [10, 11]. However, the presence of a p53
inducible RNR small subunit (p53R2) enables the de
novo pathway to provide dNTPs even for non-cycling
cells [12]. Furthermore, TS activity is a prerequisite for
the de novo synthesis of dTMP. In rodents both TK1
and TS activity are developmentally down-regulated and
decreased to minimal levels within 2 weeks after birth
[13, 14]. To our knowledge the levels of TS and p53R2
and the distribution of cytosolic deoxynucleoside kinases
in adult animal tissues have not been reported.
Deficiencies in TK2 or p53R2 cause fatal myopathy
and/or encephalomyopathy in humans [15, 16]. Tissue
specific mtDNA depletion has also been observed in
TK2 H126N knock-in and TK2 knock-out mice as well
as p53R2 knock-out mice [16–18]. Defects in nucleotide
metabolism have also been linked to nuclear genome in-
stability and premature aging [19–21].
To understand why TK2 and p53R2 deficiency led to
mtDNA depletion syndromes (MDS) we studied the
levels and distribution of enzymes in dTMP synthesis in
major adult rat tissues. A cytosolic isoform of TK2 was
partially purified and characterized in addition to the
mitochondrial TK2. TS activity and the levels of TS pro-
tein, as well as the levels of p53R2 protein were
determined.
Results
Isolation of mitochondrial and cytosolic fractions
Mitochondrial and cytosolic fractions were prepared
from fresh adult rats tissues according to standard pro-
cedures [22]. The quality was accessed by western blot
analysis using antibodies against cytochrome c oxidase
subunit 4 (COX4), which is located in the mitochondrial
inner membrane; and cytochrome c, which is loosely as-
sociated with mitochondrial inner membrane. Both
COX4 and cytochrome c were detected in all the mito-
chondrial preparations but also in the cytosol prepar-
ation of heart tissue (Fig. S1A). The absence of COX4
and cytochrome c in the cytosol preparations of brain,
liver, kidney, spleen, lung and skeletal muscle demon-
strated minimal contamination by mitochondria. The
presence of COX4 and cytochrome c in the heart cytosol
preparation indicated the presence of mitochondria,
most likely due to that the isolation procedure was
unable to release interfibrillar mitochondria from
heart tissue as described earlier [23]. Therefore, ultra-
centrifugation was used to remove all mitochondria
from heart cytosol preparation and in the final heart
cytosol preparation no cytochrome c was detected
(Fig. S1B).
However, the lack of cytochrome c and COX 4 in the
cytosol preparations cannot exclude leakage of mito-
chondrial matrix proteins into the cytosol during prepar-
ation. Therefore, the mitochondrial matrix protein
citrate synthase activity was assayed in both the mito-
chondrial and cytosolic extracts. As shown in Table 1
citrate synthase activity was mainly detected in mito-
chondrial fractions and the citrate synthase activity
Fig. 1 Schematic presentation of dTMP synthesis pathways. TK1, cytosolic thymidine kinase 1; TK2, thymidine kinase 2; TS, thymidylate synthase;
dCK, deoxycytidine kinase; R1, ribonucleotide reductase large subunit; p53R2, p53 inducible ribonucleotide reductase small subunit
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detected in cytosolic fractions was approximately 5–9%
of that in the corresponding mitochondrial fractions.
These results strongly indicated that there was minimal
leakage of mitochondrial protein into the cytosolic
fractions.
Identification and characterization of a cytosolic TK2-like
enzyme
TK2 is known as mitochondrial enzyme. Since both dT
and dC phosphorylating activities were present in the
cytosolic fractions from all tissues (Table S1), we wanted
to clarify which enzymes are responsible for the ob-
served dT and dC phosphorylating activities. The cyto-
solic proteins were separated by anionic (DEAE-
Sephadex) and cationic (CM-Sepharose) exchange col-
umn chromatography. The bound proteins were eluted
with a linear KCl gradient. In brain, heart, spleen, kid-
ney, lung, and skeletal muscle both dT and dC
Table 1 Citrate synthase activity in mitochondrial and cytosolic
preparations
Citrate synthase activity (μmol/min/mg)
Tissue Mitochondrial Cytosolic Cytosolic/mitochondrial
Liver 12.1 ± 0.5 0.70 ± 0.04 0.057
Heart 54.3 ± 1.3 5.02 ± 0.18 0.092
Brain 45.8 ± 3.4 3.13 ± 0.06 0.068
Kidney 28.3 ± 1.2 2.23 ± 0.09 0.078
Spleen 41.8 ± 1.0 2.03 ± 0.03 0.048
Lung 61.0 ± 1.7 3.50 ± 0.06 0.057
Skeletal muscle 31.0 ± 1.2 2.6 ± 0.18 0.083
Fig. 2 Distribution of cytosolic deoxynucleoside kinases in adult rat tissues determined by anionic (a, c, e, g, i, k and m) and cationic (b, d, f, h, j,
l, and n) exchange column chromatography. Cytosolic proteins from each tissue were applied to a anionic exchange (DEAE-sephadex) column
and the flow through (unbound protein) was applied to a cationic exchange (CM-sepharose) column. The bound proteins were then eluted with
KCl gradient. Fractions were collected and assayed using tritium labeled dT (filled circles) and dC (open circles) as substrate. TK2 and dCK bind to
DEAE-Sephadex column and TK2 eluted at low KCl concentration and dCK eluted at higher KCl concentration. TK1 binds to CM-Sepharose
column and eluted at low KCl concentration
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phosphorylating activity co-eluted in the same DEAE
chromatography fractions (Fig. 2a, c, e, g, i and m), at
concentration range similar to the elution profile of
mitochondrial TK2 [24]. Under these conditions cyto-
solic dCK, if present, eluted with higher KCl concentra-
tions [25], as shown in DEAE chromatograms from
spleen, lung, liver, and skeletal muscle (Fig. 2e, i, k and
m). TK1 protein, however, does not bind to the DEAE-
Sephadex column but binds to the CM-Sepharose col-
umn and eluted at low KCl concentration [26], as shown
in the liver and spleen chromatograms (Fig. 2f and l).
The DEAE fractions containing the dT and dC phos-
phorylating activity from heart and brain were pooled
and characterized further. The heart enzyme had appar-
ent KM values for dT and dC of 38 ± 1.9 and 88.9 ±
12 μM and Vmax values of 25.9 ± 0.5 and 32.8 ± 2.4 nmol/
min/mg, respectively (Fig. 3a and b). The brain enzyme
had apparent KM values of 52.5 ± 6.1 (dT) and 113.1 ±
23 μM (dC) and Vmax values of 21.3 ± 1.1 (dT) and
23.1 ± 2.8 (dC) nmol/min/mg, respectively (Fig. 3c and
d). Thus, the heart and brain cytosolic TK2-like enzymes
showed similar substrate specificity to the native and re-
combinant mitochondrial TK2 [26–28].
These results demonstrated the presence of a putative
cytosolic TK2-like enzyme in all tissues except liver, and
the presence of dCK in spleen, lung, liver, and skeletal
muscle, and TK1 in liver, spleen, brain and heart. To
our knowledge this is the first time it is shown in the cy-
tosols from major tissues in adult animals.
Comparison of mitochondrial and cytosolic thymidine
kinase activities
Mitochondrial and cytosolic thymidine kinase activities
were determined using tritium labelled dT as substrate
[29]. High levels of mitochondrial TK2 activity was de-
tected in brain, spleen and lung mitochondria, while
intermediate levels were found in liver, heart and kidney
mitochondria; in skeletal muscle mitochondria TK2 ac-
tivity was the lowest. In most tissues the cytosolic dT
kinase activity was very low as compared with the mito-
chondrial TK2 activity, except in spleen which had the
highest cytosolic dT kinase activity due to the presence
of TK1. Overall spleen had the highest and skeletal
muscle had the lowest total thymidine kinase activity
(Fig. 4a).
The concentrations of mitochondrial TK2 protein
Mitochondrial TK2 protein was determined by an im-
munoprecipitation method using anti-TK2 antibodies.
Recombinant human mitochondrial TK2 was used as
Fig. 3 Substrate saturation curves of partially purified cytosolic TK2-like enzyme. Substrates used were [3H]-dT and [3H]-dC. Heart (a and b) and
brain (c and d)
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Fig. 4 Mitochondrial and cytosolic thymidine kinase activities in rat tissues (a) and Mitochondrial TK2 protein levels (b). Mitochondrial TK2 protein
levels were determined by immunoprecipitation followed by western blot analysis using TK2 specific antibodies. The band intensity was
quantified and converted to ng TK2 protein per mg mitochondrial protein using recombinant human TK2 as standard. The results are presented
as mean ± SD. A representative image from IP-western blot is shown. COX 4 was used as loading control in crude extracts before
immunoprecipitation. Numbers 1 to 7 represents liver, heart, brain, kidney, spleen, lung and skeletal muscle
Fig. 5 p53R2 protein level in cytosolic extracts determined by immunoprecipitation and western blot analysis. The band intensity was quantified
and shown as mean ± SD. A representative image from IP-western blot is shown. β-actin was used as loading control in crude extracts before
immunoprecipitation. Numbers 1 to 7 represents liver, heart, brain, kidney, spleen, lung and skeletal muscle
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standard in subsequent western blot in order to quantify
the level of mitochondrial TK2. As shown in Fig. 4b
mitochondrial TK2 protein levels were in the range of
20–60 ng per mg total mitochondrial protein. Liver
mitochondria contained the highest amount of TK2 pro-
tein, heart and spleen mitochondria contained ~ 2/3 of
that in liver mitochondria. In brain, kidney, lung and
skeletal muscle the TK2 levels were similar, and was ~
1/3 of that of liver. These results demonstrated a lack of
correlation between TK2 activity and protein levels and
suggested that a post-translational regulation mechanism
may be in operation.
Ribonucleotide reductase (RNR) and p53R2
An attempt to measure RNR activity using radiolabelled
CDP was not successful, probably due to low levels of
RNR activity and/or interfering enzymes in crude ex-
tracts. In order to estimate the cytosolic RNR activity we
determined the p53R2 protein concentrations in cyto-
solic and mitochondrial extracts by using immunopre-
cipitation method with p53R2 specific antibodies. In the
cytosolic extracts the p53R2 levels were similar in brain,
kidney, skeletal muscle, heart, spleen and lung, but lower
in liver (Fig. 5). No p53R2 protein could be detected in
the mitochondrial extracts.
Thymidylate synthase
The cytosolic TS activity was highest in spleen and low-
est in kidney. Intermediate TS activity was found in liver,
lung, heart and brain, and low activity in skeletal muscle
and kidney (Fig. 6a). There was no detectable TS activity
in mitochondrial extracts from most tissues, except that
a low TS activity was detected in spleen mitochondrial
extracts, which might be due to contamination by cyto-
solic TS (Fig. 6a).
TS protein level was high in heart, brain, spleen and
skeletal muscle but low in liver, kidney, and lung ex-
tracts (Fig. 6b). There was no detectable TS protein in
mitochondrial extracts from liver, heart, brain, and kid-
ney but a very low level of TS protein was detected in
spleen and skeletal muscle (Fig. 6b). Furthermore, TS
protein detected in heart and brain showed higher mo-
lecular mass on SDS-PAGE as compared with other
tissues (Fig. 6b), suggesting post-translational modifica-
tions. In heart and skeletal muscle TS protein levels
were high but activity levels were low. The reason for
this discrepancy is not known but other factors such as
post-translation modifications may affect TS activity. As
shown in earlier studies, phosphorylation on Ser-12 [30]
or S-glutathionylation on Cys-195 lead to decreased ac-
tivity [31].
Discussion
Defect nucleotide metabolism causes devastating MDS
and also nuclear genome instability [19–21, 32]. Current
deoxynucleoside based therapy has been shown to im-
prove the quality of life and lifespan in human patients
and animal models [33–35]. To understand how this
treatment works we need to study the enzymes in nu-
cleotide metabolism.
Here we have determined the levels of TKs, TS and
p53R2 in adult rat tissues at the sub-cellular level in
order to estimate the capacity of the salvage and the de
novo synthesis of dTMP in normal tissues. We have also
Fig. 6 Thymidylate synthase activity (a) and protein level (b) in rat tissues. Equal volume of cytosolic and mitochondrial extracts was used in the
TS activity (expressed as pmol/min/mg) and radiolabelling of TS protein experiments using [32P]-5-fluoro-dUMP. The intensity of each band was
quantified and normalized to the amount of protein used in the experiments and expressed as arbitrary unit/mg protein. A representative
autoradiograph image is shown. Results are mean ± SD. Number 1 to 7 represents liver, heart, brain, kidney, spleen, lung and skeletal muscle
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clarified which cytosolic enzyme e.g. TK1, TK2, and
dCK is present in different tissues, and characterized a
putative cytosolic TK2-like enzyme partially purified
from brain and heart. The cytosolic TK2-like enzyme
showed similar substrate specificity as the mitochondrial
form. At present we do not know if the cytosolic TK2-
like enzyme is an alternative spliced form of mitochon-
drial TK2 or encoded by a new gene, since in most hu-
man tissues multiple mitochondrial TK2 mRNA
transcripts exist [27, 36] and a TK2 isoform lacking
mitochondrial targeting sequence has been reported pre-
viously [36] in addition to the full length TK2 sequence
with mitochondrial leader sequence [5, 28]. Nonetheless
we show here that the kinetic properties of the two vari-
ant TK2s are very similar, and further investigation of
the cytosolic TK2-like enzyme is warranted. If the cyto-
solic TK2-like enzyme described here is encoded by a
different gene it may contribute to and help to explain
the therapeutic effects of deoxynucleoside treatment in
TK2 knock-out mouse models as well as in human pa-
tients with TK2 deficiency [33–35, 37, 38]. Furthermore,
the presence of cytosolic dCK may also contribute to the
salvage synthesis of thymidine nucleotide (Fig. 1).
Mitochondrial TK2 activity was dominating in all tis-
sues as compared with the cytosolic TK2-like activity
[7]. Although there is a large variation in the mitochon-
drial TK2 activity from tissue to tissue, mitochondrial
TK2 protein levels showed only 2 to 3-fold difference.
The lack of correlation between mitochondrial TK2 ac-
tivity and protein concentrations in liver, heart and skel-
etal muscle is most likely due to the high respiration
rates in these tissues. This may result in oxidative stress
induced modifications that inactivate and/or degrade the
mitochondrial TK2 protein as demonstrated earlier [39].
Nonetheless the specific activity of mitochondrial TK2
determined here in rat tissues showed a clear correlation
to the levels of dTTP pools but not dCTP pools deter-
mined previously in rat liver, heart, brain and skeletal
muscle mitochondria [32, 40].
The de novo synthesis of dNTPs relies on RNR activity
and in non-proliferating tissues the RNR activity is
dependent on the expression of p53R2 [10, 12]. In all tis-
sues p53R2 levels were similar except liver for which the
p53R2 level was low. For the de novo synthesis of dTTP
TS activity is required. High TS activity was found in
spleen, but low in all other tissues, indicating a generally
low capacity of de novo dTMP synthesis.
Using tissue mRNA expression data from Expression
Atlas [41] for Sprague Dawley we compared the mRNA
levels of TK2, TS and p53R2 with protein concentrations
determined here in the corresponding tissue and could not
find clear-cut correlations (Fig. S3. A, B, C). The lack of
correlation between mRNA and protein could also be seen
in case of TK1 and dCK; high level of TK1 mRNA was
found in kidney, spleen, lung and liver, however, TK1 pro-
tein was mainly detected in spleen and liver but not kidney
and lung; dCK mRNA was highly expressed in brain but
we could not detected any dCK protein (Fig. S3. D). The
lack of correlation between the levels of mRNA and protein
may be explained by post-translational modifications such
as S-glutathionylation affecting protein stability [30, 31, 39].
In mice, p53R2 knockout results in mtDNA depletion,
however, over expression of p53R2 alone or in combin-
ation with Rrm1 (coding for ribonucleotide reductase R1
subunit) lead to increased dATP and dCTP pools but
surprisingly a decreased dTTP pool in skeletal muscle
[16, 42]. In TK2 knockout mice a significant decrease in
dTTP but not dCTP pools was observed in heart and
brain tissues [13]. All these results point to that de novo
synthesis can provide sufficient dCTP but not dTTP for
mtDNA synthesis. Furthermore, in most non-
proliferating tissues TK2 is apparently responsible for
the overall dTMP synthesis needed for mtDNA replica-
tion and nuclear DNA repair [43].
Conclusions
This study suggests that the mitochondrial TK2 and the
cytosolic TK2-like enzymes are the main enzymes for the
synthesis of pyrimidine nucleotides in non-proliferating
tissues; while TK1 and dCK contribute to pyrimidine nu-
cleotides synthesis in tissues with high fractions of prolif-
erating cells. The limiting factor in the de novo synthesis
of dTMP is the level of TS activity. Of course different
species may have differences in the expression and levels
of these enzymes and the observed phenotypic differences
between TK2 knock-out mice and TK2-deficient human
patients strongly indicate tissue specificity differences be-
tween the two species. Recent studies in TK2 H126N
knock-in and TK2 knock-out mice clearly substantiate
this conclusion [38, 44]. Future studies of these human
enzymes will most likely aid improvements of the thera-
peutic approaches for mitochondrial disorders caused by
defect in nucleotide metabolism.
Methods
Materials
Radioactive substances [methyl-3H]-thymidine (dT, 20
Ci/mmol) and [γ-32P] ATP (3000 Ci/mmol) were ob-
tained from Perkin Elmer. [5-3H]-deoxycytidine (dC, 27
mCi/ml) and [5-3H]-deoxyuridine monophosphate
(dUMP, 24 Ci/mmol) were from Moravek Biochemicals,
Inc. [32P]-5FdUMP (5-fluorodeoxyuridine 5′-monopho-
sphate) was prepared from 5FdUrd (5-fluorodeoxyuri-
dine) and [γ-32P]-ATP in an enzymatic reaction
catalysed by thymidine kinase. Antibodies against cyto-
chrome c oxidase subunit 4 (COX 4) and cytochrome c
were purchased from CLONTECH. Goat anti-TK2 anti-
bodies, rabbit anti-R2 and goat anti-p53R2 antibodies
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were from Santa Cruz biotechnology, Inc. DTNB (5,5′-
dithiobis(2-nitrobenzoic acid)) and Oxaloacetate were
from Sigma-Adrich. Acetyl-CoA was from Roche Diag-
nostics GmbH.
Enzyme assays
Deoxynucleoside kinase activity was determined by using
either [3H]-dT or [3H]-dC as substrate as described previ-
ously [27] with the addition of 6-chloro-5 amino-uracil
(1 μM) and NaF (15mM) to inhibit thymidine phosphor-
ylase and 5′-nucleotidase activities. Thymidylate synthase
activity was determined by using the tritium release assay
[45] with [5-3H]-dUMP as substrate. NaF (15mM) was
added to inhibit 5′-nucleotidase/phosphatase activity. All
the assays were performed in triplicates for each tissue
type from individual animal and the results were pre-
sented as mean ± SD in pmol product formed/min/mg.
Citrate synthase activity was determined in both mito-
chondrial and cytosolic extracts at room temperature
(21 °C) as previously described [46]. Briefly, mitochon-
drial and cytosolic extracts (40 μg) were added to a reac-
tion mixture containing 0.2M Tris/HCl, pH 8.0, 0.1 mM
DTNB (5,5′-dithiobis[2-nitrobenzoic acid], and 0.3 mM
Acetyl-CoA in a total volume of 475 μl and incubated
for 2 min, and then the reaction was started by addition
of 25 μl Oxaloacetate (10 mM). The formation of prod-
uct was monitored at 412 nm over 3 min in a spectro-
photometer. The assays were repeated four times and
the results were presented as mean ± SD.
Isolation of intact mitochondria and cytosol
Mitochondria and cytosol were prepared by differential
centrifugation method [22] using fresh tissues from adult
rats (Sprague Dawley, 10 weeks old, purchased from Scan-
bur LabAnimal, Danmark, n = 5). The rats were housed at
animal facility at Uppsala University according to inter-
national regulations and the experiment was approved by
the local ethical committee in Uppsala, Sweden. The rats
were sacrificed by using a mixture of medicine air and suc-
cessive increase of carbon dioxide in the cage. Organs were
removed and used directly. The cytosol and mitochondria
preparations were stored in aliquots at − 70 °C until further
analysis. Mitochondrial proteins were extracted by sonic-
ation in ice/water bath after addition of 0.5% NP-40 (Noni-
det P-40). After centrifugation (16,000 x g for 20min at
4 °C) the clear supernatant was used in the assays. Protein
concentrations were determined by the Bio-Rad protein
assay using bovine serum albumin as standard.
Anionic and cationic exchange chromatography and
partial purification of a cytosolic form of a TK2-like
enzyme
Cytosolic extracts were applied to a pre-equilibrated an-
ionic exchange column (DEAE fast flow, GE Healthcare,
column size 1 ml) in buffer A (25 mM Tris/HCl, pH 7.6,
2 mM MgCl2, 1 mM Dithiothreitol (DTT) and 15% Gly-
cerol) and eluted with linear gradient (0–0.3M) of KCl
in buffer A. Fractions (0.5 ml) were collected and assayed
for dT and dC kinase activity. In case of the cationic ex-
change chromatography the flow through from DEAE-
Sephadex column was collected and applied to a pre-
equilibrated CM-Sepharose column (GE Healthcare, col-
umn size 1 ml) in buffer A and eluted with linear gradi-
ent (0–0.3 M) of KCl in buffer A. Fractions (0.5 ml) were
collected and assayed for dT and dC kinase activity.
Fractions containing TK2 activity from the DEAE
chromatography of brain and heart cytosolic extracts
were pooled, the protein concentration was determined
and used in kinetic studies with tritium labelled dT and
dC as the variable substrate at fixed ATP concentration.
The kinetic parameters were calculated by using the Sig-
maPlot enzyme kinetics module 1.1 (SPSS Science).
Western blots analysis and immunoprecipitation
Mitochondrial and cytosolic proteins (10 μg/lane) were
separated on 14% SDS-polyacrylamide gels and trans-
ferred to polyvinylidene difluoride (PVDF) membranes,
which were then probed for 2 h with anti-cytochrome c
oxidase subunit 4 (COX 4) (1:500 dilution) and anti-
cytochrome c (1:200 dilution), or anti-β-actin (1:1000 di-
lution) antibodies at room temperature and detected by
the enhanced chemiluminescence detection system (GE
healthcare).
Immunoprecipitation was performed with 1 mg cyto-
solic or mitochondrial proteins following standard pro-
tocols. A rabbit anti-R2 antibody or goat anti TK2
antibody was added to the cytosolic respective mito-
chondrial extracts and incubated over night at 4 °C. Pro-
tein A Sepharose was added and incubated for
additional 2 h, then collected by centrifugation. After
washing 3 times with PBS, 50 μl SDS sample buffer was
added to the slurry. After boiling for 5 min and brief
centrifugation 20 μl supernatant was applied to 12%
SDS- polyacrylamide gels. After electrophoresis the pro-
teins were transferred to PVDF membranes. A goat anti-
p53R2 antibody or rabbit anti-TK2 antibody was used in
western blot to detect p53R2 protein or TK2 protein, re-
spectively. Band intensities were quantified by using
Image Gauge software version 3.3 (Fuji Photofilm Co.
Ltd). In order to quantify mitochondrial TK2 protein in
the western,blots recombinant human TK2 (2, 5, 10, and
25 ng) were loaded on the same gel and the band inten-
sity was quantified and a standard curve was constructed
(supplementary figure S2). The amount of TK2 in these
tissue samples was calculated based on the standard
curve. The results were presented as mean ± SD in arbi-
trary units/mg protein in case of p53R2, and ng/mg
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protein in case of mitochondrial TK2 protein using re-
combinant TK2 as standard.
Determination of TS protein levels
5-fluoro-2′-deoxyuridine-5′-monophosphate (5FdUMP)
forms a covalent ternary complex with the TS protein in
the presence of methylene tetrahydrofolate. Therefore,
we used [32P]-5FdUMP to determine the levels of TS.
Mitochondrial and cytosolic extracts (20 μl) were mixed
with 10 μl reaction mixture containing 25mM MgCl2,
0.2 mM methylene tetrahydrofolate, 0.2 mM Cytidine 5′-
monophosphate, 20 mM DTT and 5 μM [32P]-5FdUMP.
The mixtures were incubated at 37 °C for 2 h and then
stopped by addition of the SDS sample buffer (5 μl).
After heating at 95 °C for 3 min 15 μl was loaded onto
12% SDS-PAGE gels. After electrophoresis the gels were
fixed in methanol/acetic acid and the radiolabelled pro-
tein bands were visualized by autoradiography. The band
intensity was quantified by using Image Gauge software
version 3.3 (Fuji Photofilm Co. Ltd). The results were
presented as mean ± SD in arbitrary unit/mg protein.
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Additional file 1: Table S1. dT and dC kinase activity in mitochondrial
and cytosolic extracts. Figure S1. Assessment of the quality of
mitochondrial and cytosolic preparations by using western blot analyses
using anti cytochrome c oxidase subunit 4 (COX4) and anti-cytochrome c
antibodies. Mitochondrial and cytosolic preparation from liver, heart,
brain, spleen, kidney, and skeletal muscle (A); and lung and heart (B). Fig-
ure S2. Recombinant TK2 was used as standard in western blot analysis
for determination of mitochondrial TK2 in rat tissue mitochondrial ex-
tracts. TK2 (2, 5, 10, and 25 ng) was loaded onto the same gel for western
blot analysis using TK2 specific antibody and the band intensity was
quantified and plotted against the amount of TK2 protein in each lane to
generate a standard curve by using linear regression analysis. Figure S3.
Direct correlation analysis of mRNA levels of TK2 (A), p53R2 (B) and TS (C)
with protein concentration determined by western blot analyses (TK2
and p53R2) and radiolabeling (TS). Tissues mRNA expression data/heat
map is from Expression Atlas (D)
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